Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8,917 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of elbasvir/grazoprevir in treatment-naive Chinese adults with hepatitis C virus infection: A randomized trial.
Wei L, Jia JD, Duan ZP, Wang FS, Niu JQ, Xie W, Huang WX, Zhang MX, Huang Y, Wang MR, Wu SM, Zhao YR, Jia ZS, Zhao XM, Mu SM, Liang LW, Wang Z, Puenpatom A, Hwang P, Robertson MN, Ingravallo P, Asante-Appiah E, Wei B, Evans B, Hanna GJ, Talwani R. Wei L, et al. Among authors: xie w. JGH Open. 2020 Jul 15;4(6):1065-1073. doi: 10.1002/jgh3.12387. eCollection 2020 Dec. JGH Open. 2020. PMID: 33319038 Free PMC article.
A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin.
Wei L, Zhang M, Xu M, Chuang WL, Lu W, Xie W, Jia Z, Gong G, Li Y, Bae SH, Yang YF, Xie Q, Lin S, Chen X, Niu J, Jia J, Garimella T, Torbeyns A, McPhee F, Treitel M, Yin PD, Mo L. Wei L, et al. Among authors: xie w, xie q. J Gastroenterol Hepatol. 2016 Nov;31(11):1860-1867. doi: 10.1111/jgh.13379. J Gastroenterol Hepatol. 2016. PMID: 27003037 Clinical Trial.
A multicenter, randomized, double-blind trial comparing the efficacy and safety of TUDCA and UDCA in Chinese patients with primary biliary cholangitis.
Ma H, Zeng M, Han Y, Yan H, Tang H, Sheng J, Hu H, Cheng L, Xie Q, Zhu Y, Chen G, Gao Z, Xie W, Wang J, Wu S, Wang G, Miao X, Fu X, Duan L, Xu J, Wei L, Shi G, Chen C, Chen M, Ning Q, Yao C, Jia J. Ma H, et al. Among authors: xie w, xie q. Medicine (Baltimore). 2016 Nov;95(47):e5391. doi: 10.1097/MD.0000000000005391. Medicine (Baltimore). 2016. PMID: 27893675 Free PMC article. Clinical Trial.
CSH guidelines for the diagnosis and treatment of drug-induced liver injury.
Yu YC, Mao YM, Chen CW, Chen JJ, Chen J, Cong WM, Ding Y, Duan ZP, Fu QC, Guo XY, Hu P, Hu XQ, Jia JD, Lai RT, Li DL, Liu YX, Lu LG, Ma SW, Ma X, Nan YM, Ren H, Shen T, Wang H, Wang JY, Wang TL, Wang XJ, Wei L, Xie Q, Xie W, Yang CQ, Yang DL, Yu YY, Zeng MD, Zhang L, Zhao XY, Zhuang H; Drug-induced Liver Injury (DILI) Study Group; Chinese Society of Hepatology (CSH); Chinese Medical Association (CMA). Yu YC, et al. Among authors: xie w, xie q. Hepatol Int. 2017 May;11(3):221-241. doi: 10.1007/s12072-017-9793-2. Epub 2017 Apr 12. Hepatol Int. 2017. PMID: 28405790 Free PMC article.
Daclatasvir plus asunaprevir in treatment-naïve patients with hepatitis C virus genotype 1b infection.
Wei L, Wang FS, Zhang MX, Jia JD, Yakovlev AA, Xie W, Burnevich E, Niu JQ, Jung YJ, Jiang XJ, Xu M, Chen XY, Xie Q, Li J, Hou JL, Tang H, Dou XG, Gandhi Y, Hu WH, McPhee F, Noviello S, Treitel M, Mo L, Deng J. Wei L, et al. Among authors: xie w, xie q. World J Gastroenterol. 2018 Mar 28;24(12):1361-1372. doi: 10.3748/wjg.v24.i12.1361. World J Gastroenterol. 2018. PMID: 29599611 Free PMC article. Clinical Trial.
Guidelines of prevention and treatment of nonalcoholic fatty liver disease (2018, China).
Fan JG, Wei L, Zhuang H; National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association; Fatty Liver Disease Expert Committee, Chinese Medical Doctor Association. Fan JG, et al. J Dig Dis. 2019 Apr;20(4):163-173. doi: 10.1111/1751-2980.12685. Epub 2018 Dec 11. J Dig Dis. 2019. PMID: 30444584 No abstract available.
Efficacy and Safety of All-oral, 12-week Ravidasvir Plus Ritonavir-boosted Danoprevir and Ribavirin in Treatment-naïve Noncirrhotic HCV Genotype 1 Patients: Results from a Phase 2/3 Clinical Trial in China.
Xu X, Feng B, Guan Y, Zheng S, Sheng J, Yang X, Ma Y, Huang Y, Kang Y, Wen X, Li J, Tan Y, He Q, Xie Q, Wang M, An P, Gong G, Liu H, Ning Q, Hua R, Ning B, Xie W, Zhang J, Huang W, Yang Y, Lin M, Zhao Y, Yu Y, Jia J, Yang D, Chen L, Ye Y, Nan Y, Gong Z, Zhang Q, Hu P, Wang F, Li Y, Li D, Jia Z, Hou J, Chen C, Wu JJ, Wei L. Xu X, et al. Among authors: xie w, xie q. J Clin Transl Hepatol. 2019 Sep 28;7(3):213-220. doi: 10.14218/JCTH.2019.00033. Epub 2019 Sep 30. J Clin Transl Hepatol. 2019. PMID: 31608212 Free PMC article.
Baseline Characteristics and Treatment Patterns of the Patients Recruited to the China Registry of Hepatitis B.
Shan S, You H, Niu J, Shang J, Xie W, Zhang Y, Li X, Ren H, Tang H, Ding H, Wang X, Nan Y, Dou X, Han T, Zhang L, Liu X, Deng C, Cheng J, Wang X, Xie Q, Lin S, Huang Y, Xu Y, Xiong Y, Li W, Yan X, Piao H, Huang W, Lu Q, Gong W, Li S, Hu X, Zhang X, Liu S, Li Y, Yang D, Li H, Yang C, Cheng M, Zhang L, Zheng H, Luo X, Lin F, Wang L, Xu G, Xu X, Wei L, Hou J, Duan Z, Zhuang H, Yang X, Kong Y, Jia J; CR-HepB study group, Beijing, China. Shan S, et al. Among authors: xie w, xie q. J Clin Transl Hepatol. 2019 Dec 28;7(4):322-328. doi: 10.14218/JCTH.2019.00052. Epub 2019 Dec 20. J Clin Transl Hepatol. 2019. PMID: 31915601 Free PMC article.
Glecaprevir-pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies- a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2).
Wei L, Wang G, Alami NN, Xie W, Heo J, Xie Q, Zhang M, Kim YJ, Lim SG, Fredrick LM, Lu W, Liu W, Kalluri HV, Krishnan P, Tripathi R, Mobashery N, Burroughs M, Asatryan A, Jia J, Hou J. Wei L, et al. Among authors: xie w, xie q. Lancet Gastroenterol Hepatol. 2020 Sep;5(9):839-849. doi: 10.1016/S2468-1253(20)30086-8. Epub 2020 Jul 16. Lancet Gastroenterol Hepatol. 2020. PMID: 32682494 Clinical Trial.
8,917 results